A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program

Recently approved in Europe and Australia, the multi-component meningococcal B vaccine, 4CMenB (Bexsero(®), Novartis Vaccines and Diagnostics), contains three surface-exposed recombinant proteins (fHbp, NadA, and NHBA) and New Zealand strain outer membrane vesicles (NZ OMV) with PorA 1.4 antigenicit...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: O’Ryan, Miguel, Stoddard, Jeffrey, Toneatto, Daniela, Wassil, James, Dull, Peter M.
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2013
Teme:
Review Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3890039/
https://ncbi.nlm.nih.gov/pubmed/24338083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-013-0155-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items